Novel Immunotherapies for B-Cell Lymphomas and Leukemias

被引：1

作者：

Tees, Michael T. ^{[1
]}

Sokol, Lubomir ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, 12902 Magnolia Dr, Tampa, FL 33612 USA

来源：

AMERICAN JOURNAL OF THERAPEUTICS | 2016年 / 23卷 / 05期

关键词：

non-Hodgkin lymphoma; Hodgkin lymphoma; B-cell neoplasms; immunotherapy; radioimmunotherapy; monoclonal antibody; antibody-drug conjugate; NON-HODGKIN-LYMPHOMA; PHASE-I TRIAL; IMMUNOCONJUGATE INOTUZUMAB OZOGAMICIN; MONOCLONAL-ANTIBODY LUCATUMUMAB; INNATE IMMUNE-RESPONSES; OPEN-LABEL; BRENTUXIMAB VEDOTIN; FOLLICULAR LYMPHOMA; CLINICAL ACTIVITY; PLUS RITUXIMAB;

D O I：

10.1097/MJT.0000000000000145

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Current immunotherapeutic agents under investigation have the potential to significantly expand our ability to effectively treat B-cell malignancies. New disease targets, novel strategies to deliver therapy, and advanced agents that work to manipulate the immune system are a few of the ways immunotherapy has quickly evolved. Novel targeted and immune-modifying therapies may demonstrate early potential but unique toxicities and other limitations, such as difficulties in administration, must also be acknowledged. This review provides a comprehensive assessment of the current immunotherapies under investigation against B-cell malignancies.

引用

页码：E1157 / E1181

页数：25

共 50 条

[1] Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias
Tees, Michael T.
Sokol, Lubomir
AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (02) : E498 - E520
[2] Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas
Ohanian, Maro
Kantarjian, Hagop
Guy, Daniel
Thomas, Deborah
Jabbour, Elias
O'Brien, Susan
EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (04) : 601 - 611
[3] CAR T cell therapy for B-cell lymphomas
Chavez, Julio C.
Locke, Frederick L.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (02) : 135 - 146
[4] Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab
Ku, Matthew
Chong, Geoff
Hawkes, Eliza A.
BLOOD REVIEWS, 2017, 31 (01) : 23 - 35
[5] Upcoming immunotherapeutic combinations for B-cell lymphoma
Greve, Patrick
Meyer-Wentrup, Friederike A. G.
Peperzak, Victor
Boes, Marianne
IMMUNOTHERAPY ADVANCES, 2021, 1 (01):
[6] Immunotherapy in aggressive B-cell lymphomas
Jacobson, Caron A.
Armand, Philippe
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (03) : 299 - 305
[7] Ibrutinib and Indolent B-Cell Lymphomas
Akinleye, Akintunde
Furqan, Muhammad
Adekunle, Oluwaseyi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (04): : 253 - 260
[8] Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas
Ruan, J.
Shah, B.
Martin, P.
Schuster, S. J.
ANNALS OF ONCOLOGY, 2016, 27 (07) : 1226 - 1234
[9] Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas
Trabolsi, Asaad
Arumov, Artavazd
Schatz, Jonathan H.
BLOOD CANCER JOURNAL, 2024, 14 (01)
[10] Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy
Sircar, Anuvrat
Chowdhury, Sayan Mullick
Hart, Amber
Bell, William Connor
Singh, Satishkumar
Sehgal, Lalit
Epperla, Narendranath
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)

← 1 2 3 4 5 →